Skip to main content
. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777

Fig 3. Kaplan–Meier curves for the secondary composite endpoint of doubling of serum creatinine or ESRD.

Fig 3

Kaplan–Meier curves show the proportion of patients who reached the composite endpoint of doubling of serum creatinine or ESRD in the placebo and octreotide-LAR groups during the 3-year study period. *Adjusted by age, sex, and baseline serum creatinine.°Adjusted by age, sex, and baseline serum creatinine and total kidney volume. ESRD, end-stage renal disease; HR, hazard ratio; octreotide-LAR, octreotide long-acting release.